U.S. Sex Cord Gonadal Stromal Tumor Market Size, Share & Forecast 2026–2032

ID: MR-11818 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Sex Cord-Gonadal Stromal Tumor Market
  • ✓Market Size 2024: USD 285 million
  • ✓Market Size 2032: USD 430 million
  • ✓CAGR: 5.3%
  • ✓Market Definition: Revenue from diagnosis, surgical resection, systemic and hormonal therapy, and molecular testing for sex cord-gonadal stromal tumors in the United States. Covers granulosa cell, Sertoli-Leydig, and thecoma-fibroma histologies.
  • ✓Leading Companies: Roche, AstraZeneca, Merck & Co., Thermo Fisher Scientific, Illumina
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Serum Marker Coverage Gap: Serum inhibin B and anti-Müllerian hormone testing for granulosa cell tumor surveillance depends on lab-by-lab Medicare coverage decisions. Reference laboratories that secure local coverage before 2027 will consolidate recurrence monitoring volume from community hospitals.
FINDING 02
Tumor-Agnostic Market Access: Analysts assume Orphan Drug Act exclusivity will attract sponsors to sex cord-stromal tumors. Tumor-agnostic approvals, such as Merck's pembrolizumab for MSI-high solid tumors, now define the route to market, because biomarker labels let sponsors skip histology-specific trials.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock In Biomarker Agreements: Diagnostic and pharmaceutical sponsors should pursue FDA companion diagnostic agreements for FOXL2 testing before the PDUFA VIII commitment letter reaches Congress in January 2027, since early agreements secure label language. Investors should favor CLIA-certified laboratories with NCD 90.2 coverage.

Sex Cord-Gonadal Stromal Tumors in the U.S.: Market Overview

The U.S. market for sex cord-gonadal stromal tumors was valued at USD 285 million in 2024 and spans diagnostics, surgery, systemic therapy and companion testing. Granulosa cell tumors dominate, representing roughly 70 percent of cases, followed by Sertoli-Leydig cell tumors and thecomas. Demand is concentrated in gynecologic oncology centers, where the volume of rare histologies is high enough to justify specialist pathology review.

Policy has shaped the market's current form in two directions. The federal government, through the National Cancer Institute's Surveillance, Epidemiology, and End Results Program and the NRG Oncology cooperative groups, has been the dominant force in defining incidence data and treatment evidence. Private manufacturers have led assay development, drug commercialization, and companion diagnostic deployment, with pharmaceutical firms relying on Orphan Drug Act incentives to justify development costs.

Policy-Driven Growth in U.S. Sex Cord-Gonadal Stromal Tumor Care

The Orphan Drug Act of 1983 grants seven years of market exclusivity to drugs designated for rare conditions, and Section 45C of the Internal Revenue Code provides a 25 percent tax credit on qualified clinical testing costs. These incentives translate into pipeline investment because sponsors can recover development costs in a market where patient numbers are small. The Act's threshold of fewer than 200,000 U.S. patients qualifies sex cord-stromal subtypes, which lets sponsors pursue designation for granulosa cell tumor programs.

PDUFA VII, the user-fee agreement covering fiscal years 2023 through 2027, commits the FDA to review goals of 10 months after filing for standard and 6 months after filing for priority new molecular entities. Faster review shortens the time before a therapy reaches oncologists treating rare ovarian histologies. Medicare National Coverage Determination 90.2 covers next-generation sequencing for beneficiaries with advanced cancer when a qualifying test is used, which expands molecular profiling of granulosa cell tumors and drives assay volume.

Regulatory Barriers and Compliance Costs

Laboratory-developed tests remain governed primarily by the Clinical Laboratory Improvement Amendments of 1988, administered by CMS with the CDC under 42 CFR Part 493. FDA's May 2024 final rule extending device oversight to laboratory-developed tests was vacated by the U.S. District Court for the Eastern District of Texas on March 31, 2025, in American Clinical Laboratory Association v. FDA. Laboratories offering FOXL2 or inhibin testing must therefore maintain CLIA certificates, proficiency testing enrollment, and qualified personnel, with certificates renewed every two years.

Price controls add a second layer. The Inflation Reduction Act of 2022 created the Medicare Drug Price Negotiation Program, administered by CMS, which selects drugs annually and applies negotiated prices first effective in 2026. The ORPHAN Cures Act, enacted in July 2025, broadened the exclusion for orphan-only drugs, but sponsors whose sex cord-stromal therapies carry a second non-orphan indication lose that protection, which raises compliance planning costs for multi-indication programs.

Policy-Created Opportunities in the United States

Medicare National Coverage Determination 90.2 creates demand for next-generation sequencing across advanced gynecologic cancers. Laboratories able to deliver FOXL2 C134W testing, which is present in more than 95 percent of adult granulosa cell tumors, can capture reimbursed volume under CMS coverage rules. Separately, the NIH Office of Rare Diseases Research funds the Rare Diseases Clinical Research Network, whose natural history studies underpin orphan designation applications for sex cord-stromal programs.

CMS's Transitional Coverage for Emerging Technologies pathway, finalized in 2024, provides five years of expedited Medicare coverage for eligible FDA Breakthrough Devices, which benefits biomarker assays for these tumors. Larotrectinib, approved by the FDA in 2018 for NTRK gene fusion-positive solid tumors, shows how biomarker labels open indications for rare histologies, a model sponsors can apply to sex cord-stromal subsets.

Market at a Glance

MetricValue
Market Size 2024USD 285 million
Market Size 2032USD 430 million
Growth Rate (CAGR)5.3%
Most Critical Decision FactorMedicare coverage of molecular testing for granulosa cell tumors
Largest RegionSouth (U.S. Census region)
Competitive StructureConsolidated among pharmaceutical firms; fragmented among laboratories

Leading Market Participants

  • Roche
  • AstraZeneca
  • Merck & Co.
  • GSK
  • Eli Lilly
  • Thermo Fisher Scientific
  • Illumina
  • Beckman Coulter
  • Siemens Healthineers
  • Myriad Genetics

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 301 et seq., which the FDA enforces for drugs and devices, including companion diagnostics requiring premarket approval under 21 CFR Part 814. The Orphan Drug Act (Public Law 97-414) and the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. 263a) complete the core framework. Key compliance requirements include investigational new drug submissions under 21 CFR Part 312, informed consent under 21 CFR Part 50, orphan designation requests to the FDA's Office of Orphan Products Development, and CLIA certification for every testing site.

Upcoming changes include the PDUFA VIII commitment letter, which the FDA must transmit to Congress in January 2027 ahead of reauthorization by September 2027. Congress will decide in 2026 and 2027 whether to legislate oversight of laboratory tests following the court vacatur. Compared with regional peers, the U.S. framework is faster but less uniform: the EU's Regulation (EU) 2017/746 on in vitro diagnostic devices, with transition deadlines extended by Regulation (EU) 2024/1860 to between 2027 and 2029, requires conformity assessment for every test, while the EU Orphan Medicinal Products Regulation (EC) No 141/2000 grants ten years of exclusivity against the U.S. seven.

Long-Term Policy Outlook for U.S. Sex Cord-Gonadal Stromal Tumors

The 2027 PDUFA VIII reauthorization will set review goals and user-fee funding through 2032, determining how quickly biomarker-defined labels for these tumors reach the market. Without new legislation, CLIA remains the governing framework for laboratory tests through 2032, and laboratories will continue to build validation data under that regime. Congressional action on laboratory test oversight is the single largest unresolved variable for diagnostic revenue.

CMS revisions to NCD 90.2 and expanded TCET eligibility will shift reimbursement toward molecular profiling of granulosa cell tumors. Annual drug selection caps under the Medicare Drug Price Negotiation Program will rise through the decade, increasing pricing pressure on multi-indication therapies. These changes will push growth toward diagnostics and biomarker-matched therapies, lifting the U.S. market from USD 285 million in 2024 to USD 430 million by 2032 at a 5.3% CAGR.

Frequently Asked Questions

No histology-specific approval exists, so sponsors use an investigational new drug application under 21 CFR Part 312 and a new drug application under 21 CFR Part 314. Sponsors can also request Orphan Drug designation from the FDA's Office of Orphan Products Development.
Yes, under National Coverage Determination 90.2 for beneficiaries with advanced cancer when a qualifying test is used. Coverage depends on the test being an FDA-approved test or a test performed in a CLIA-certified laboratory.
The FDA's 2024 laboratory-developed test rule was vacated in March 2025, so CLIA administered by CMS remains the primary framework. Congress has not yet legislated replacement oversight.
The Inflation Reduction Act excludes drugs approved only for orphan indications from Medicare price negotiation. The ORPHAN Cures Act, enacted in July 2025, broadened this exclusion for orphan-only drugs.
Sponsors must post trial results on ClinicalTrials.gov under 42 CFR Part 11 within one year of the primary completion date. Failure to report can result in civil monetary penalties under the Food and Drug Administration Amendments Act of 2007.

Market Segmentation

By Tumor Type
  • Granulosa Cell Tumors
  • Sertoli-Leydig Cell Tumors
  • Thecomas and Fibromas
  • Sex Cord Tumors with Annular Tubules
  • Others
By Treatment Modality
  • Surgical Resection
  • Platinum-Based Chemotherapy
  • Aromatase Inhibitor Therapy
  • Targeted and Immunotherapy
  • Radiotherapy
By End User
  • Academic Medical Centers
  • Community Hospitals
  • Reference Laboratories
  • Ambulatory Surgical Centers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Sex Cord-Gonadal Stromal Tumor - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Tumor Type Insights
4.1 Granulosa Cell Tumors
4.2 Sertoli-Leydig Cell Tumors
4.3 Thecomas and Fibromas
4.4 Sex Cord Tumors with Annular Tubules
4.5 Others
Chapter 05 Treatment Modality Insights
5.1 Surgical Resection
5.2 Platinum-Based Chemotherapy
5.3 Aromatase Inhibitor Therapy
5.4 Targeted and Immunotherapy
5.5 Others
Chapter 06 End User Insights
6.1 Academic Medical Centers
6.2 Community Hospitals
6.3 Reference Laboratories
6.4 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Roche
7.2.2 AstraZeneca
7.2.3 Merck & Co.
7.2.4 GSK
7.2.5 Eli Lilly
7.2.6 Thermo Fisher Scientific
7.2.7 Illumina
7.2.8 Beckman Coulter
7.2.9 Siemens Healthineers
7.2.10 Myriad Genetics
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.